Elsevier

Clinical Therapeutics

Volume 25, Issue 1, January 2003, Pages 178-193
Clinical Therapeutics

Original research
Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial

https://doi.org/10.1016/S0149-2918(03)90023-3Get rights and content

Abstract

Background: Parallel with the development of hypotheses regarding cholinergic involvement in geriatric memory dysfunction, the first attempts to treat patients with Alzheimer's disease (AD) involved the cholinergic-precursor loading approach. Despite encouraging early results, well-controlled clinical trials did not confirm a clinical utility of cholinergic precursors such as choline and lecithin (phosphatidylcholine) in AD.

Objective: This study assessed the efficacy and tolerability of the cholinergic precursor choline alfoscerate (CA) in the treatment of cognitive impairment due to mild to moderate AD.

Methods: In this multicenter, double-blind, randomized, placebo-controlled trial, patients affected by mild to moderate dementia of the Alzheimer type were treated with CA (400-mg capsules) or placebo capsules, 3 times daily, for 180 days. Efficacy outcome measures that were assessed at the beginning of the investigation and after 90 and 180 days of treatment included scores of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Alzheimer's Disease Assessment Scale-Behavioral Subscale (ADAS-Behav), all items of the Alzheimer's Disease Assessment Scale (ADAS-Total), and the Clinical Global Impression (CGI) scale. The Global Improvement Scale (GIS) score was assessed after 90 and 180 days of treatment.

References (39)

  • D.S Geldmacher

    Cost-effective recognition and diagnosis of dementia

    Semin Neurol

    (2002)
  • E.K Perry et al.

    Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia

    BMJ

    (1978)
  • E.K Perry

    The cholinergic hypothesis—ten years on

    Br Med Bull

    (1986)
  • S.D Brinkman et al.

    Lecithin and memory training in suspected Alzheimer's disease

    J Gerontol

    (1982)
  • E Davis et al.

    Therapeutic intervention in dementia

    Crit Rev Neurobiol

    (1993)
  • S Govoni et al.

    Effects of alpha-glycerylphosphorylcholine in counteracting drug-induced amnesia: Through cholinergic and non-cholinergic mechanisms [in Italian]

    Basi Raz Ter

    (1991)
  • P.L Canonico et al.

    Neurochemical and behavioral effects of alpha-glycerylphosphorylcholine [in Italian]

    Basi Raz Ter

    (1990)
  • R.D Venn

    The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale

    Gerontology

    (1983)
  • R Di Perri et al.

    A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia

    J Int Med Res

    (1991)
  • Cited by (122)

    • Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies

      2021, Free Radical Biology and Medicine
      Citation Excerpt :

      N-acetyl cysteine demonstrated impact on cognitive performance for individuals with AD [230,481] and improved cognitive performance in a single case study for an individual with AD already receiving folic acid and B12 [481]. Acetyl-l-carnitine improved cognitive performance [230,482,483], with superior effect on individuals <65yrs of age [484,485]; also improved for cognitive performance and BPSD when administered to individuals diagnosed with AD that were already receiving, but were not responsive to, pharmacological agents (donepezil or rivastigmine) [486]. S-adenosyl methionine provided limited efficacy for cognitive performance in AD [230,487,488] and for depression [489,490] the latter is relevant since depression can potentiate the conversion of MCI to AD [98,491] and can negatively influence overall outcomes and is associated with the ultimate need for institutionalization [1,3,204].

    View all citing articles on Scopus
    View full text